Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.38 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | TDP2 | O95551 | 1/20 | 0.36 |
| ▸ | DCK | P27707 | 3/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4721598 | 1.00 | MAP3K14 (0.38) | MAP3K14SSTR2ERN1RORCTMEM97 | |
| SCHEMBL5630487 | 0.92 | TTR (0.37) | ERN1DCKTTRMAPT | |
| SCHEMBL4721723 | 0.92 | TTR (0.37) | ERN1DCKTTRMAPT | |
| SCHEMBL4723812 | 0.88 | OTUD7B (0.42) | ERN1DPP4PDK2 | |
| SCHEMBL4762782 | 0.88 | OTUD7B (0.42) | ERN1DPP4PDK2 | |
| SCHEMBL4718394 | 0.86 | ERN1 (0.43) | ERN1DCK | |
| SCHEMBL5654301 | 0.86 | ERN1 (0.43) | ERN1DCK | |
| SCHEMBL4719581 | 0.82 | HSD11B1 (0.45) | SCN9A | |
| SCHEMBL5629543 | 0.82 | HSD11B1 (0.45) | SCN9A | |
| SCHEMBL5629422 | 0.82 | HSD11B1 (0.41) | PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070129345-A1 | Lactam compounds and methods of using the same | INCYTE CORPORATION | 2007-06-07 | — | — | US | claimed |
| US-8193207-B2 | Lactam compounds and methods of using the same | INCYTE CORPORATION (US) | 2012-06-05 | — | — | US | disclosed |
| EP-1957494-A2 | LACTAM COMPOUNDS AND METHODS OF USING THE SAME | Incyte Corporation (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007067504-A2 | LACTAM COMPOUNDS AND METHODS OF USING THE SAME | INCYTE CORPORATION (US) | 2007-06-14 | — | — | WO | disclosed |
| US-20070129345-A1 | Lactam compounds and methods of using the same | INCYTE CORPORATION | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129345-A1 | Lactam compounds and methods of using the same | HSD11B1, HSD17B11, HSD17B1 | MAP3K14 4319/4885SSTR2 4783/4885ERN1 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.